Targeting hyperactive TGFBR2 for treating MYOCD deficient lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Drug resistance limits cancer therapy success, often due to tumor suppressor gene (TSG) loss.
• Developing strategies for resistant tumors is a critical clinical need.

Purpose of the Study:

• To investigate the role of MYOCD as a tumor suppressor gene in lung cancer.
• To explore MYOCD's function in regulating lung cancer stem cells and its therapeutic implications.

Main Methods:

• In vitro and in vivo experiments to confirm MYOCD's tumor suppressive function.
• Analysis of MYOCD's mechanism in inhibiting lung cancer stemness.
• Investigating MYOCD's interaction with the TGFBR2 promoter and epigenetic silencing complex.

Main Results:

• MYOCD demonstrates potent inhibition of lung cancer stem cell stemness.
• MYOCD recruits the PRMT5/MEP50 complex to epigenetically silence TGFBR2.
• Non-small cell lung cancer (NSCLC) cells lacking MYOCD show heightened sensitivity to TGFBR kinase inhibitors (TGFBRi).

Conclusions:

• Loss of MYOCD function creates a vulnerability in lung cancer cells.
• TGFBRi can be a targeted therapy for MYOCD-deficient lung cancers.
• Combination therapies involving TGFBRi and stemness inhibitors show promise for treating MYOCD-deficient lung cancers.